Paliperidone Palmitate Six-Month Dosing With Missed-Dose Flexibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with psychiatric disorders, particularly schizophrenia, face challenges with adherence to monthly or longer dosing regimens of antipsychotic medications like paliperidone palmitate, leading to relapse and other negative consequences, and there is a need for flexible dosing schedules and methods to manage missed doses and weight gain.
Innovation Solution
A six-month dosing regimen for paliperidone palmitate injections with a flexible dosing window of up to two weeks before or three weeks after the scheduled date, re-initiation regimens for missed doses, and methods to stabilize or decrease weight gain, including specific dosing schedules and routes of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a six-month dosing regimen is used, then adherence is enhanced and relapse risk is reduced, but flexibility in dosing is limited
Solution Approach 1:
The patent applies dynamics by establishing a flexible dosing window that allows the second dose to be administered between 5 to 11 months after the first dose. This dynamic approach enables adjustment of the dosing schedule within a range rather than fixing it to a single time point, thereby maintaining adherence benefits while accommodating patient needs and clinical circumstances.
2Ease of operation
If a fixed six-month dosing interval is used, then treatment simplicity is improved, but ability to manage missed doses is worsened
Solution Approach 1:
The patent resolves this contradiction by introducing a dynamic dosing window (5 to 11 months) that provides clear guidance for both routine administration and missed dose scenarios. This maintains treatment simplicity through defined parameters while enabling flexible management of missed doses without requiring complex individualized recalibration.
3Quantity of substance
If paliperidone palmitate is administered as an aqueous nanosuspension, then solubility is improved, but dosing frequency must be extended
Solution Approach 1:
The patent applies parameter changes by utilizing the aqueous nanosuspension formulation which alters the physical state and solubility characteristics of paliperidone palmitate. This formulation enables extended release over 5-11 months, transforming the drug's release profile to achieve both improved solubility and appropriately extended dosing interval for maintenance therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances adherence, reduces relapse risk, and mitigates weight gain, providing sustained therapeutic effects and flexibility in dosing for patients with psychiatric disorders.
Implementation Method 1
Because of extreme low water solubility, paliperidone esters such as paliperidone palmitate dissolve slowly after an intramuscular injection before being hydrolyzed to paliperidone and made available in the systemic circulation.
Data Source
AI summary
The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.